Antonoglou Christos, Papanas Nikolaos, Maltezos Efstratios
Second Department of Internal Medicine, University Hospital of Alexandroupolis, Dragana 68100, Alexandroupolis, Greece.
Curr Vasc Pharmacol. 2014;12(5):745-50. doi: 10.2174/15701611113119990127.
Diabetic foot ulcers arise from neuropathy and/or ischaemia. The diabetic foot is associated with cardiovascular disease (CVD) and excess mortality. Lipid-lowering therapy reduces CVD morbidity and mortality in diabetic patients with foot ulcers. In particular, statins decrease CVD mortality and improve survival in diabetic foot patients, while fibrates benefit patients with a specific lipid profile. Statins reduce progression of the local disease, improving symptoms and reducing amputations, mainly due to their impact on peripheral arterial disease. Fibrates appear to reduce amputations by improving neuropathy. They also improve ulcer healing and reduce recurrence. This review assesses the role of hypolipidaemic treatment in diabetic foot patients.
糖尿病足溃疡由神经病变和/或缺血引起。糖尿病足与心血管疾病（CVD）及过高死亡率相关。降脂治疗可降低患有足溃疡的糖尿病患者的CVD发病率和死亡率。特别是，他汀类药物可降低糖尿病足患者的CVD死亡率并提高生存率，而贝特类药物则使具有特定血脂谱的患者受益。他汀类药物可减少局部疾病的进展，改善症状并减少截肢，主要是因其对外周动脉疾病的影响。贝特类药物似乎通过改善神经病变来减少截肢。它们还可促进溃疡愈合并减少复发。本综述评估了降血脂治疗在糖尿病足患者中的作用。
